Mesoblast (ASX:MSB) joined the S&P/ASX 200 Index before market open on Thursday, according to a same-day filing with the Australian bourse.
The company, which develops treatment for life-threatening inflammatory conditions, saw shares down almost 4% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。